Long non‑coding RNA T cell factor 7 is associated with increased disease risk and poor prognosis, and promotes cell proliferation, attenuates cell apoptosis and miR‑200c expression in multiple myeloma
- Tianling Ding
- Ruoyu Deng
- Ting Huang
Affiliations: Department of Hematology, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China, Shanghai Qeejen Bio‑tech Institution, Shanghai 200434, P.R. China, Department of Oncology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
- Published online on: December 18, 2020 https://doi.org/10.3892/ol.2020.12390
Copyright: © Ding
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The aim of the present study was to investigate the association of long non‑coding RNA T cell factor 7 (lncRNA TCF7) with disease risk, prognosis and its cellular function in multiple myeloma (MM). A total of 132 de novo symptomatic patients with MM and 50 controls were enrolled. Plasma cells from patients with MM and controls were separated from bone marrow samples to detect lncRNA TCF7 expression using reverse transcription‑quantitative PCR. In addition, treatment responses, event‑free survival (EFS) and overall survival (OS) were measured. The effects of lncRNA TCF7 on proliferation, apoptosis and microRNA‑200c (miR‑200c) expression were assessed by gain‑ and loss‑of‑function experiments in RPMI‑8226 and U‑266 cells. The results demonstrated that lncRNA TCF7 expression was upregulated in patients with MM compared with controls, and the receiver operating characteristic curve revealed that lncRNA TCF7 could distinguish patients with MM from controls with an area under the curve of 0.793 (95% CI, 0.725‑0.861). In patients with MM, high lncRNA TCF7 expression was associated with higher β2‑microglobulin, more advanced International Staging System stage and increased t (14; 16) mutations. Furthermore, it was demonstrated that lncRNA TCF7 was downregulated in patients with complete response (CR) compared with patients without CR. Furthermore, high lncRNA TCF7 expression predicted worse EFS and OS. lncRNA TCF7 also promoted cell proliferation, whereas it reduced cell apoptosis and miR‑200c expression in RPMI‑8226 and U‑266 cells. In conclusion, the present results suggested that lncRNA TCF7 may be used as a potential biomarker and as a treatment target for MM.